Molecular Targeting Technologies

Molecular Targeting Technologies, Inc. (MTTI) is a clinical-stage biotechnology company headquartered in West Chester, Pennsylvania. Its central asset is EvaThera, a target-agnostic pharmacokinetic engineering platform based on Evans Blue-mediated reversible albumin binding: an Evans Blue-derived moiety is attached to an existing targeting ligand and chelator, so that after the radioligand binds its target it also transiently binds circulating albumin, extending its circulation time, increasing tumour exposure and prolonging tumour retention without requiring discovery of a new molecular target.

The platform's lead clinical application is 177Lu-DOTA-EB-TATE (EBTATE), an albumin-binding somatostatin receptor 2 (SSTR2)-targeted radiopharmaceutical for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), originally developed and licensed from the US National Institutes of Health; MTTI is advancing it toward pivotal Phase III development, with US trials stated to have begun at Memorial Sloan Kettering Cancer Center. Clinical experience with EBTATE reported by the company across 81 patients found tumour retention for up to 15 days, roughly eight-fold higher tumour uptake and/or retention compared with 177Lu-DOTA-TATE (Lutathera's active ingredient), a 50% objective response rate, 100% disease control rate, 36-month median progression-free survival, no observed kidney toxicity through one year of follow-up, and clinical activity achieved using only about 12.5% of the cumulative radioactivity used in conventional four-cycle PRRT (data presented at SNMMI 2026 and the 2026 Targeted Radiopharmaceuticals Summit; not yet FDA-approved).

MTTI is extending EvaThera beyond SSTR2 to additional programmes including EB-RGD (integrin alphaVbeta3, aimed at glioblastoma and non-small-cell lung cancer), EB-FAPI (fibroblast activation protein) and EB-GRPR (gastrin-releasing peptide receptor), using both lutetium-177 and actinium-225 (225Ac-EBTATE, being developed for small-cell lung cancer, reported preclinically comparable to 225Ac-DOTATATE at roughly 40% of the administered dose). In 2026, Pharma Tech Outlook named EvaThera its Radiopharmaceutical Therapy Solution of the Year, and MTTI describes itself as actively seeking licensing and co-development partnerships to apply EvaThera to third-party radiopharmaceutical programmes.